Innovative Medicines Initiative (IMI 2)

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI has a budget of €3.276 billion for the period 2014-2024. Half of this comes from the EU. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources.

IMI was launched in 2008 and currently has 46 ongoing projects, with more in the pipeline. Some focus on specific health issues such as neurological conditions (Alzheimer’s disease, schizophrenia, depression, chronic pain, and autism), diabetes, lung disease, oncology, inflammation & infection, tuberculosis, and obesity. Others focus on broader challenges in drug development like drug and vaccine safety, knowledge management, the sustainability of chemical drug production, the use of stem cells for drug discovery, drug behaviour in the body, the creation of a European platform to discover novel medicines, and antimicrobial resistance. In addition to research projects, IMI supports education and training projects

Giving researchers from diverse sectors the opportunity to participate in ambitious public-private partnerships that will pave the way for the development of the medicines of the future. IMI warmly encourages small and medium-sized enterprises (SMEs), medium-sized companies, patients’ organisations, regulatory authorities, academic teams, industry, hospitals and other organisations to form consortia and apply to participate in the new IMI projects.

 

 

Open Calls:

 

IMI2 Call 14 is now open!

 

Topics:

• Targeted immune intervention for the management of non-response and relapse

• Non-invasive clinical molecular imaging of immune cells

• Development of a platform for federated and privacy-preserving machine learning in support of drug discovery

• Centre of excellence – remote decentralised clinical trials

 

Deadline for submission: 14/6/2018

Call text:  

Webinars for each of the topics: http://www.imi.europa.eu/news-events/events/imi2-call-14-webinars

 

 

Important links

IMI homepage

IMI proposal template

IMI evaltiation form (for call 13 and onward)

IMI manual for submission, evaluation and grant award

IMI annotated modeal grant agreement

Other relevant documents

 

 

 

 

 

 

 

 

 

 

 

  

 

Jump to page content